NEW YORK, 27 March 2021 (GLOBE NEWSWIRE) – WHY: Rosen Law Firm, a global investment rights law firm, is reminding customers of Athenex, Inc. securities. (NASDAQ: ATNX) between August 7, 2019 and February 26, 2021, inclusive (the “class time”), of what matters May 3, 2021 plaintiff main date.
SO WHAT: If you purchased Athenex securities during Class Time you may be entitled to compensation without incurring any costs or expenses through a contingent tax arrangement.
WHAT TO DO: To get involved in Athenex class action, go to http://www.rosenlegal.com/cases-register-2051.html or call Phillip Kim, Esq. free of charge at 866-767-3653 or email [email protected] or [email protected] for information on class activity. A class action lawsuit has already been filed. If you want to be the main complaint, you have to move the Court no later than May 3, 2021. A chief planner is a representative party acting on behalf of other class members in administering the law.
WHY: We encourage investors to choose certified advice with a history of success in management positions. Issuing companies often do not have comparable knowledge or resources. Rosen Law Firm represents investors around the globe, focusing their use in securities class actions and legalizing shareholder sub-securities. Rosen Law Firm has executed the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was ranked at No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017. The firm has been ranked in the top 4 annually since 2013 and has get back hundreds of millions of dollars to investors. In 2019 alone the company received more than $ 438 million for investors. In 2020 founding partner Laurence Rosen was named by law360 as the Titan Bar of Plaintiffs. Many of the firm’s lawyers are recognized by Lawdragon and Super Lawyers.
CASE INFORMATION: According to a lawsuit, defendants during the Class Period made false and / or misleading and / or failed statements: (1) that the data included in the Paclitaxel New Oral Drug Application and Encequidar (“NDA”) poses a safety risk to patients against an increase in sequalae associated with neutropenia; (2) the uncertainty about the results of the primary endpoint of target response rate (“ORR”) at week 19 was made by blinded median study (“BICR”); (3) the BICR resolution and readability process may have introduced an unmixed bias and effect on BICR; (4) The Athenex Phase 3 study used to diagnose the NDA was inappropriate and poorly conducted in a population of patients with metastatic breast cancer representative of the U.S. population, so the FDA recommends new such clinical trial; (5) as a result, the FDA was expected not to approve NDA Athenex in its current form; and (6) as a result, the defendants’ public statements were misleading and misleading at all material times. Once the real details entered the market, the lawsuit alleges that investors suffered damage.
To get involved in Athenex class action, go to http://www.rosenlegal.com/cases-register-2051.html or call Phillip Kim, Esq. free of charge at 866-767-3653 or email [email protected] or [email protected] for information on class activity.
No classes were confirmed. Until a class is confirmed, you will not be represented by an adviser unless you book one. You can choose a consultant of your choice. You can also remain an absent class member and do nothing at this stage. An investor’s ability to share in any future improvement is not dependent on serving as a key complaint.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Lawyer advertising. Previous results do not guarantee a similar result.
——————————-
Contact information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Law Firm Rosen, PA
275 Madison Avenue, 40th floor
New York, NY 10016
Phone: (212) 686-1060
Hole free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com